China's Abbisko jumps on positive clinical trial results for achondroplasia drug
21/09/2026 05:38
BUZZ-China's Abbisko jumps on positive clinical trial results for achondroplasia drug ** Shares of clinical-stage biopharmaceutical firm Abbisko Cayman 2256.HK jump 7.9% to HK$8.95, on course for the biggest one-day pct gain since June 29
** Stock hits the highest level since September 9
** Chinese oncology therapies developer says its unit Abbisko Therapeutics has announced positive preliminary efficacy results from phase II clinical trial of lavengratinib (ABSK061) for treatment of achondroplasia in children
** YTD, stock down 31.7%, while Hang Seng Biotech Index .HSBIO up 15.9%
(Reporting by Donny Kwok)
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration